Literature DB >> 32318884

Hospitalizations for Acute on Chronic Liver Failure at Academic Compared to Non-academic Centers Have Higher Mortality.

Ashwani K Singal1, Zunirah Ahmed2, Page Axley3, Sumant Arora4, Juan P Arab5, Allen Haas6, Yong-Fang Kuo6, Patrick S Kamath7.   

Abstract

BACKGROUND AND AIM: Acute on chronic liver failure (ACLF) in patients with cirrhosis has high short-term mortality. Data comparing ACLF admissions to academic centers (AC) and non-academic centers (NAC) are scanty.
METHODS: National Inpatient Sample (2006-2014) was queried for admissions with cirrhosis and ACLF using the ICD-09 codes, and was stratified to AC or NAC.
RESULTS: Of 1,928,764 admissions with cirrhosis (2006-2014), 112,174 (5. 9%) had ACLF. 6.7% of 1,018,568 cirrhosis admissions to AC had ACLF versus 5% of 910,196 admissions to NAC, P < 0.0001. Proportion of ACLF admissions to AC increased from 49% during 2006-2008 to 59% during 2012-2014. In a cohort of 73,630 ACLF admissions (36,615 each to AC and NAC) matched for patient demographics, cirrhosis etiology, number of comorbidities, elective versus emergent admission, ACLF grade, and type of organ failure. In-hospital mortality declined by 7% over the study period, but remained higher in AC (46% vs. 42%, P < 0.001), with 11% increased odds for in-hospital mortality compared to admission to NAC. Further admissions to AC versus NAC had higher median (IQR) length of stay at 13 (6-25) versus 11 (5-20) days, with higher median (IQR) hospital charges: 138,239 (66,772-275,603) versus 116,209 (55,767-232,699) USD, P < 0.001 for both.
CONCLUSION: Patients with ACLF have high in-hospital mortality. Further, this is higher among admissions to AC. Although the in-hospital mortality is improving, strategies are needed on early identification of patients with futility of care for early discussion on goals of care, and optimal utilization of hospital resources among admissions with ACLF.

Entities:  

Keywords:  ACLF; Admissions; Cirrhosis; Health care burden; Resources

Year:  2020        PMID: 32318884     DOI: 10.1007/s10620-020-06263-w

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  5 in total

1.  Early Liver Transplantation: An Evolving Therapeutic Option for Alcohol-Associated Liver Disease.

Authors:  Mohamed A Elfeki; Ashwani K Singal
Journal:  J Clin Exp Hepatol       Date:  2021-10-28

2.  Higher Frequency of Hospital-Acquired Infections but Similar In-Hospital Mortality Among Admissions With Alcoholic Hepatitis at Academic vs. Non-academic Centers.

Authors:  Muhammad Waleed; Mohamed A Abdallah; Yong-Fang Kuo; Juan P Arab; Robert Wong; Ashwani K Singal
Journal:  Front Physiol       Date:  2020-12-03       Impact factor: 4.566

3.  Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA.

Authors:  Ashwani K Singal; Yong-Fang Kuo; Juan P Arab; Ramon Bataller
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

4.  Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).

Authors:  César Jiménez; Meritxell Ventura-Cots; Margarita Sala; Margalida Calafat; Montserrat Garcia-Retortillo; Isabel Cirera; Nuria Cañete; Germán Soriano; María Poca; Macarena Simón-Talero; José Altamirano; Michael Lucey; Guadalupe Garcia-Tsao; Robert S Brown; Robert F Schwabe; Elizabeth C Verna; Bernd Schnabl; Francisco Bosques-Padilla; Philippe Mathurin; Juan Caballería; Alexandre Louvet; Debbie L Shawcross; Juan G Abraldes; Joan Genescà; Ramon Bataller; Víctor Vargas
Journal:  Liver Int       Date:  2022-03-07       Impact factor: 8.754

5.  The Jieduan-Niwan (JDNW) Formula Ameliorates Hepatocyte Apoptosis: A Study of the Inhibition of E2F1-Mediated Apoptosis Signaling Pathways in Acute-on-Chronic Liver Failure (ACLF) Using Rats.

Authors:  Weixin Hou; Yulin Hao; Wenlong Yang; Tian Tian; Peng Fang; Yuqiong Du; Lianyin Gao; Yanbin Gao; Qiuyun Zhang
Journal:  Drug Des Devel Ther       Date:  2021-09-08       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.